Inhibikase Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
* Inhibikase Therapeutics Inc IKT.OQ IKT.O is expected
to show
a fall in quarterly revenue when it reports results on March
31.
*
* Refinitiv's mean analyst estimate for Inhibikase
Therapeutics
Inc is for a loss of 19 cents per share.
* The one available analyst rating on the shares is
"hold".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
This summary was machine generated March 29 at 20:16 GMT. All
figures in US dollars unless otherwise stated
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary